格隆汇3月17日丨神威药业(02877.HK)宣布，公司将于2026年3月27日星期五于香港湾仔港湾道18号中环 广场31楼3109室举行董事会会议，藉以(其中包括)批准发布公司及其附属公司截至2025年12月31日止年 度业绩及考虑宣派股息。 ...

( 在開曼群島註冊成立之有限責任公司 ) ( 股份代號： 2877) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED 中國神威藥業集團有限公司 承董事會命 中國神威藥業集團有限公司 主席 李振江 香港，二零二六年三月十七日 於本公告刊發日期，執行董事包括李振江先生、信蘊霞女士及李惠民先生。非執行董事為周 文成先生。獨立非執行董事包括廖舜輝先生、姚逸安先生及王桂華女士。 董事會會議通告 中國神威藥業集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 二零二六年三月二十七日星期五於香港灣仔港灣道18號中環廣場31樓3109室舉行董事 會會議，藉以（其中包括）批准發佈本公司及其附屬公司截至二零二五年十二月三十 一日止年度業績及考慮宣派股息。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000, ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 HKD | | 500,000,000 | 本月底法定/註冊股本總額： HKD 500,000,000 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 50 ...

Group 1 - The company is making significant progress in the research and development of innovative drugs, particularly the Seletong capsule, which has completed Phase III clinical trials and is expected to receive production approval in 2026 and be launched in 2027 [1][2] - The Seletong capsule targets vascular dementia, which is the second most common cause of dementia after Alzheimer's disease, with an anticipated market potential as the number of elderly dementia patients in China is expected to exceed 10 million by 2025 [1][2] - The company's revenue for the first three quarters of 2025 was RMB 2.415 billion, a decrease of 16.3% year-on-year, primarily due to the impact of centralized procurement on traditional Chinese medicine products [1][3] Group 2 - The gross profit margin for the first half of 2025 decreased from 75.3% to 72.2%, attributed to rising raw material costs and price pressures from national centralized procurement [4] - The net profit margin increased from 30.0% to 37.2%, mainly due to a 20.7% reduction in sales and distribution costs and a 12.9% decrease in administrative expenses [4] - The company plans to enhance its performance recovery through new product lines like the Seletong capsule and a strong commercialization team [4] Group 3 - The company has received approval for the classic traditional Chinese medicine formula Shaoyao Gancao Decoction granules, marking it as the first approved classic formula in 2025 [3] - The company is also advancing the clinical trials for a new traditional Chinese medicine for treating chronic disease anemia, with significant clinical value shown in patients unresponsive to EPO treatment [3] - The market for traditional Chinese medicine granules is currently undergoing restructuring, with the company focusing on expanding its market presence beyond Hebei and Yunnan provinces [5] Group 4 - The company has a target price of HKD 10.04 per share, with a "buy" rating, as the product structure is expected to optimize with new drug launches [2][5] - Revenue projections for 2025-2027 are RMB 3.84 billion, RMB 4.11 billion, and RMB 4.60 billion, with net profits of RMB 929 million, RMB 1.011 billion, and RMB 1.138 billion respectively [2][5] - The company's dividend yield is currently at 6.1%, indicating a potential 22% upside from the current price [2][5]

Core Viewpoint - Shenwei Pharmaceutical (02877) has shown significant stock performance, rising over 3% to HKD 8.51, with a trading volume of HKD 10.48 million, indicating positive market sentiment towards the company [1] Group 1: Company Research and Development - Guoyuan International's report highlights Shenwei Pharmaceutical's notable achievements in traditional Chinese medicine innovation, with multiple research and clinical projects progressing smoothly [1] - The company's R&D expenses for the first half of 2025 amounted to RMB 50.37 million, representing 3.0% of its revenue [1] - Key products under development, such as Q-B-Q-F Concentrated Pills and Selotong Capsules, are advancing steadily, with Selotong Capsules having completed Phase III clinical trials [1] Group 2: Market Potential and Product Overview - Selotong Capsules, developed using modern innovative technology, target vascular dementia, which is the second most common cause of dementia after Alzheimer's disease [1] - It is projected that by 2025, the number of elderly dementia patients in China will exceed 10 million, with no effective treatment drugs currently available, indicating a vast market opportunity for Selotong Capsules [1] - The product is expected to receive production approval in 2026 and be launched in 2027, positioning it as a significant future product for the company [1]

Core Viewpoint - Shenwei Pharmaceutical (02877) has shown significant stock performance, rising over 3% to HKD 8.51, with a trading volume of HKD 10.48 million, indicating positive market sentiment towards the company [1] Group 1: Company Research and Development - Guoyuan International's report highlights Shenwei Pharmaceutical's notable achievements in traditional Chinese medicine innovation, with multiple research and clinical projects progressing smoothly [1] - The company's R&D expenses for the first half of 2025 amounted to RMB 50.37 million, representing 3.0% of its revenue [1] - Key products under development, such as Q-B-Q-F concentrated pills and Selotong capsules, are advancing steadily, with Selotong capsules having completed Phase III clinical trials [1] Group 2: Market Potential and Product Overview - Selotong capsules, developed using modern innovative technology, target vascular dementia, which is the second most common cause of dementia after Alzheimer's disease [1] - It is projected that by 2025, the number of elderly dementia patients in China will exceed 10 million, with no effective treatment drugs currently available, indicating a vast market opportunity for Selotong capsules [1] - Selotong capsules are expected to receive production approval in 2026 and be launched for sale in 2027, positioning them as a significant product in the market [1]

Core Viewpoint - Shenwei Pharmaceutical (02877) has shown significant stock performance, increasing by 3.15% to HKD 8.51, with a trading volume of HKD 10.4884 million, driven by positive research and clinical project advancements in traditional Chinese medicine [1] Group 1: Company Research and Development - Guoyuan International's report highlights Shenwei Pharmaceutical's notable achievements in innovative research, with multiple research and clinical projects progressing smoothly [1] - The company's R&D expenses for the first half of 2025 amounted to RMB 50.37 million, representing 3.0% of its revenue [1] - Key products under development, such as Q-B-Q-F Concentrated Pills and Selotong Capsules, are advancing steadily, with Selotong Capsules having completed Phase III clinical trials [1] Group 2: Market Potential and Product Overview - Selotong Capsules, developed using modern innovative technology, target vascular dementia, which is the second most common cause of dementia after Alzheimer's disease [1] - It is projected that by 2025, the number of elderly dementia patients in China will exceed 10 million, with no effective treatment drugs currently available, indicating a vast market potential for Selotong Capsules [1] - Selotong Capsules are expected to receive production approval in 2026 and be launched for sale in 2027, positioning them as a significant product in the market [1]

Investment Rating - The report assigns a "Buy" rating with a target price of HKD 10.04 per share, indicating a potential upside of 22% from the current price of HKD 8.23 [1][4][11]. Core Insights - The innovative drug Seletong Capsule is progressing well in development, having completed Phase III clinical trials and expected to receive production approval in 2026, with market potential targeting vascular dementia, which currently lacks effective treatments [2][6][7]. - The company faced revenue pressure due to industry factors such as centralized procurement, leading to a 16.3% year-on-year decline in revenue for the first three quarters of 2025 [3][8]. - Despite revenue challenges, the company has improved its net profit margin from 30.0% to 37.2% due to reduced sales and distribution costs [3][9]. Financial Summary - Revenue projections for 2025-2027 are estimated at RMB 38.4 billion, RMB 41.1 billion, and RMB 46.0 billion, respectively, with net profits expected to be RMB 9.29 billion, RMB 10.11 billion, and RMB 11.38 billion [4][11]. - The company’s gross margin decreased from 75.3% to 72.2% due to rising raw material costs and pricing pressures from centralized procurement [3][8]. - The company maintains a dividend yield of 6.1%, reflecting its commitment to returning value to shareholders [4][11].